Health systems consolidate. Insurers post record profits. Employers spend $20,000 per employee on coverage while workers fight denials alone at 11 pm. Insurance middlemen now cost more than the drugs. The system rewards delay and calls it complexity. Families call it Tuesday.

Mount Sinai and Anthem fight over 450 million dollars while 200000 patients scramble to keep their doctors and cancer treatment. Corporate contract disputes now function as leverage tactics, turning patients into bargaining chips in rate negotiations.

Blue Cross Blue Shield says insurers protect patients from high drug prices. The real world shows delays, denials, and blame shifting while patients wait, appeal, and deteriorate. A closer look at how insurers deflect responsibility in the drug pricing debate.

A new KFF poll shows prior authorization now ranks as the biggest burden in American healthcare. Delays and denials affect nearly half of insured adults, with severe mental, financial, and physical consequences. Patients across every plan agree.

We The Patients LIVE Raleigh brought patients clinicians policymakers and journalists into the same room to confront how healthcare harm actually forms. What emerged was clarity accountability and the beginning of a different kind of conversation about power trust and consequence.

Health insurers turned “medically necessary” into a denial weapon. This article breaks down how coverage policies, anonymous medical directors, and financial incentives allow insurers to override doctors and block cancer care, then outlines concrete fixes that could shut the system down.

Insurance companies promise reform while patients absorb delay and denial. From IVIG rejections to cancer imaging hold ups, this essay documents how prior authorization functions in real life and why patients now recognize the pattern.

An open letter to Mark Cuban on why the Great Healthcare Plan fails patients. It leaves PBM power intact, ignores pricing abuse, and turns transparency into theater. Patients already know how often claims get denied. We live it every day.

Blue Cross Blue Shield of North Carolina demanded another review of an already-approved, externally-reviewed IVIG infusion—48 hours before treatment. For a patient with life-threatening hypersensitivity reactions. This is how the denial machine works, and how one patient fought back and won.

Prior authorization delays cancer care and drives preventable deaths. Oncologists report treatment denials disease progression and ER visits caused by insurer delays. What began as medical review now functions as weaponized paperwork that outlasts patients.